A randomized study of 48 adolescents with type 1 diabetes, presented at the Heart in Diabetes conference, showed that those who received 2,000 mg of metformin daily for three months had reduced pulse wave velocity, reduced aortic wall sheer stress and improved far-wall diastolic carotid intima-media thickness, compared with those on placebo. Researchers also found that metformin users had improved glucose infusion rate, reduced fat mass and reduced body weight compared with the placebo group.
Metformin tied to improved CV function in youths with type 1 diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.